For a quarter century, Drug Development & Delivery has connected innovators, scientists, and industry leaders while spotlighting the technologies and ideas shaping the future of the industry. We celebrate 25 years of advancing the conversation!
As small-molecule manufacturing becomes increasingly fragmented across regions, specialist facilities, and CDMOs, every product handoff introduces new opportunities for delay and variability. A strategic bulk secondary packaging approach can help standardize product handling, improve operational control, and strengthen resilience across complex pharmaceutical supply chains.
Are your perceptions of the CMO marketplace serving your drug program—or holding it back? If you’re looking for a contract manufacturer to bring your therapy to market, you’re far from alone. Demand for manufacturing services is shaping the pharma Contract Manufacturing Industry, with analysts predicting a growth rate of nearly 7% per year until 2028. In such a competitive market, how should a project sponsor navigate the choice between one CMO and another? To find the answer, many sponsors begin by distinguishing between typical stand-alone CMOs and an embedded CMO that operates under a parent company—AbbVie, in the case of AbbVie Contract Manufacturing (AbbVie).
Advances in PCR, sequencing, automation, and molecular analysis are helping biopharma teams accelerate discovery, improve data quality, and reduce development risk. Thermo Fisher Scientific’s Dr. Anjali Shah discusses how integrated molecular biology workflows are evolving to support increasingly complex therapeutic modalities.
Cindy H. Dubin speaks with injection device developers about creating devices that are intelligent, intuitive, patient-centric systems that make advanced therapies easier, safer, and more accessible to use at home.
Shaukat Ali, PhD, and Jim Huang, PhD, discuss how the development of high- and ultra-high-concentration biologics aims to enable smaller-volume, patient-friendly subcutaneous injections.
Sarah Masucci and Crystal Salvans highlight a shift from evaluating individual syringe components independently toward system-level qualification of the complete PFS container-closure system, with the goal of simplifying development and supporting product quality and regulatory expectations.
Captisol® is a patent-protected, chemically modified beta cyclodextrin (specifically, sulfobutylether beta-cyclodextrin, or SBECD) designed to optimize the solubility, stability, and bioavailability of drugs that are otherwise difficult to deliver. Invented by scientists at the University of Kansas’ Higuchi Biosciences Center for drug development and formulation, Captisol has enabled 16 FDA-approved products—including Gilead’s VEKLURY® (remdesivir), Amgen’s KYPROLIS® (carfilzomib), Baxter International’s NEXTERONE®, Pfizer’s VFEND IV®, Sage Therapeutics’ ZULRESSO®, Novartis’ MEKINIST® (approved March 2023), and most recently SQ Innovations’ Lasix® ONYU (furosemide). Manufactured by CyDex Pharmaceuticals (a Ligand Company), Captisol stands out as the leading pharmaceutical-grade SBECD, recognized for its excellent safety and consistency record. Many Captisol-enabled products are currently in various stages of development.
Sustained release drug delivery is rapidly expanding across respiratory, ophthalmic, transdermal, and implantable applications, but translating products from development to manufacturing remains both complex and costly. Programs can stall due to material–drug compatibility issues, inconsistent release profiles, tooling-related variability, and …
A technology agnostic approach based on a fundamental understanding of API properties, a well-defined yet flexible target product profile, and a mindset for scalability and commercial relevance leads to success in formulation development and drug product design.
In a 2025 industry survey (1), 76% of respondents selected ‘risk of thermal degradation’ as a source of hesitation to pursue hot melt extrusion (HME). Concerns about heat-sensitive APIs frequently lead development teams to rule out HME early — …
The cell and gene therapy (CGT) product market is expected to grow at a very high rate of around 20-30% per year over the next 10 years. Increasing number of approvals, expansion of target diseases, accelerated investment and innovation, and …
DRUG DEVELOPMENT DIRECT RESOURCES
Upcoming eNewsletter Features:
September 16 – Capsules
September 23 – Analytical Testing
September 30 – Formulation Development
October 7 – Prefilled Syringes
October 14 – Injection Devices
October 21 – Transdermal/Topical Delivery
October 28 – Formulation Development